Yahoo Finance

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, ...
Yahoo Finance

Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune ...

NEW HAVEN, Conn and NEW YORK and SHANGHAI, April 08, 2022 (GLOBE NEWSWIRE) -- Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for ...
ascopubs.org

International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular ...

Patterns of failure and treatment for hepatocellular carcinoma after immune checkpoint inhibitors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
EurekAlert!

First-in-class drug candidate developed through NFCR funding commences phase IIB clinical trials

Three decades of NFCR basic and translational research funding to primary investigator Dr. Yung-Chi Cheng advances new systems biology paradigm for cancer treatment; world-first phase ii ...
ascopubs.org

A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring ...